Physician profile
Alvin Li
NPI 1225531007
$7,656.73
in general payments reported to CMS, 2019-2025
27 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $40.57 · 2021: $968 · 2022: $693 · 2023: $1,252 · 2024: $1,826 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,558 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,558.10 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,384.50 | 2019-2025 | |
| Lilly USA, LLC | $806.93 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $683.91 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $652.79 | 2019-2025 | |
| Incyte Corporation | $611.75 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $362.04 | 2021-2025 | Tremfya, Stelara, Simponi |
| Leo Pharma INC. | $331.00 | 2023-2025 | Adbry |
| Galderma Laboratories, L.P. | $176.71 | 2022-2025 | Nemluvio |
| Ucb, INC. | $172.76 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $154.32 | 2022-2024 | Blu-U, Odomzo |
| Arcutis Biotherapeutics, INC. | $135.44 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $134.38 | 2023-2025 | |
| Celgene Corporation | $124.55 | 2019 | |
| Kyowa Kirin, INC. | $119.14 | 2019 | |
| Vyne Pharmaceuticals INC. | $118.06 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $114.97 | 2019 | |
| Amgen INC. | $96.54 | 2021-2024 | Otezla |
| Pfizer INC. | $92.86 | 2023-2025 | |
| Biofrontera INC. | $76.04 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $63.05 | 2024-2025 | Sotyktu |
| Dermavant Sciences, INC. | $55.41 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.72 | 2022-2024 | Cyltezo |
| Organogenesis INC. | $32.99 | 2023 | Puraply |
| Organon LLC | $30.95 | 2025 | Vtama |
| Epi Health, LLC | $30.00 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.82 | 2024 | Siliq |
| Smith+Nephew, INC. | $22.10 | 2023 | Grafix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.